Lung Diseases clinical trials at UC Davis

2 research studies open to eligible people

Showing trials for

  • Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

    open to eligible people ages 18 years and up

    Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.

    Sacramento, California and other locations

  • Ralinepag to Improve Treatment Outcomes in PAH Patients

    open to eligible people ages 18 years and up

    Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.

    Sacramento, California and other locations

Our lead scientists for Lung Diseases research studies include .

Last updated: